COMMUNIQUÉS West-GlobeNewswire

Demant A/S: Change of date of publication of Interim Management Statement
02/10/2019
Company announcement no 2019- 12 2 October 2019 Change of date of publication of Interim Management Statement The date of publication of Demant’s Interim Management Statement has been changed from 7 November to 18 [...]
AgraFlora Organics Reviews Delta Greenhouse Infrastructure Upgrades; Deploys Over C$30,000,000 in PPE Expenditures
02/10/2019
VANCOUVER, British Columbia, Oct. 02, 2019 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. (“ AgraFlora ” or the “ Company ”) ( CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF ), a growth oriented and diversified [...]
New Data Presented on ASLAN’s varlitinib at ESMO 2019
02/10/2019
SINGAPORE, Oct. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the presentation of new data from a phase [...]
Nexstim Plc in Technology Licensing Discussions with a Leading California Based Academic Institution
02/10/2019
Company announcement, Helsinki 2 October 2019 at 9.00 AM (EEST) Nexstim Plc in Technology Licensing Discussions with a Leading California Based Academic Institution Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or " [...]
Top Line Results from Glaucoma Dolomites Phase 2 Trial Show Nicox’s NCX 470 Meets Primary Endpoint and Demonstrates Statistical Superiority vs Latanoprost
02/10/2019
Press Release Top Line Results from Glaucoma Dolomites Phase 2 Trial Show Nicox’s NCX 470 Meets Primary Endpoint and Demonstrates Statistical Superiority vs Latanoprost NCX 470 met the primary endpoint of non- [...]
Nicox : Les premiers résultats de l’étude de phase 2 Dolomites dans le glaucome montrent que le NCX 470 atteint le critère d’évaluation primaire et démontre une supériorité statistique vs. latanoprost
02/10/2019
Communiqué de presse Nicox : Les premiers résultats de l’étude de phase 2 Dolomites dans le glaucome montrent que le NCX 470 atteint le critère d’évaluation primaire et démontre une supériorité statistique vs. [...]
Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at 27th Annual Meeting of the European Orthopaedic Research Society
02/10/2019
Press release Gosselies, Belgium, 2 October 2019, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to [...]
Bone Therapeutics présentera des données précliniques sur les propriétés ostéogéniques d’ALLOB dans la régénération osseuse à l’occasion de la 27e réunion annuelle de l’EORS (European Orthopaedic Research Society)
02/10/2019
Communiqué de presse Gosselies, Belgique, le 2 octobre 2019, 07h00 CEST – BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE, éligible PEA-PME), société de biotechnologie spécialisée dans le développement de [...]
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
02/10/2019
Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)[1] Novartis plans FDA submission for nr-axSpA, having [...]
Novadip Biosciences Presents Clinical Case Study on Next Generation Tissue Regeneration Therapy for Critical Size Bone Reconstruction at EORS Conference
02/10/2019
Novadip Biosciences Presents Clinical Case Study on Next Generation Tissue Regeneration Therapy for Critical Size Bone Reconstruction at EORS Conference Study highlights potential benefit in rare pediatric orthopedic [...]
BriaCell Therapeutics Corp. to Clarify Record Date
02/10/2019
BERKELEY, Calif. and VANCOUVER, British Columbia, Oct. 01, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company [...]
NextCure to Present Clinical Data from NC318 Phase 1/2 Clinical Trial at 34th Annual Meeting of SITC
02/10/2019
BELTSVILLE, Md., Oct. 01, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer [...]
Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting
02/10/2019
CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, [...]
RavenQuest BioMed to Hold Third Quarter Conference Call
01/10/2019
VANCOUVER, British Columbia, Oct. 01, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “ Company ” or “ RavenQuest ”), one of Canada’s most innovative cannabis producers, [...]
Predictive Oncology Inc. Announces Proposed Public Offering of Common Stock
01/10/2019
MINNEAPOLIS, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) today announced a proposed public offering of its common stock. The offering is subject to market [...]
ContraFect to Host Development Update Call and Webcast on October 2, 2019
01/10/2019
YONKERS, N.Y., Oct. 01, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and [...]
Sonoma Pharmaceuticals Announces Management Changes
01/10/2019
Agreement with CEO and Interim CFO Bubba Sandford ends Amy Trombly Appointed as Interim CEO John Dal Poggetto Appointed as New CFO PETALUMA, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq [...]
MESA LABS DECLARES QUARTERLY DIVIDEND
01/10/2019
Lakewood, Colo., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0 [...]
Retrophin Announces Appointment of Peter Heerma as Chief Commercial Officer
01/10/2019
SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Peter Heerma as chief commercial officer, effective immediately. In this newly created position, Mr. Heerma [...]

Pages